Hypothesis
Morning light exposure advances the phosphorylation state of PER2 in the suprachiasmatic nucleus, which in turn alters the sensitivity of the ipRGC‑SCN‑adrenal axis to evening blue light, resulting in a genotype‑dependent modulation of melatonin suppression and downstream metabolic outcomes.
Mechanistic Rationale
Morning photons activate melanopsin in ipRGCs, driving glutamate release that shifts the core clock by promoting PER2 phosphorylation via CK1δ/ε. This phase advance changes the temporal window during which glucocorticoid signaling from the adrenal gland peaks. Altered glucocorticoid timing modulates hepatic PER2 expression and influences the amplitude of the evening melatonin response to blue‑light‑driven ipRGC activation. Individuals carrying the OPN4 P10L polymorphism exhibit reduced melanopsin sensitivity, leading to a blunted phase advance after morning light and a heightened melatonin suppression response to evening blue light.
Predictions & Experimental Design
- Participants stratified by OPN4 genotype (wild‑type vs P10L) will receive a standardized 30‑minute 250‑lux 480‑nm light pulse at 07:00 h for three consecutive days.
- Following the morning intervention, dim light melatonin onset (DLMO) will be measured each evening to quantify phase advance.
- On the fourth evening, participants will be exposed to a 2‑hour blue‑light enrichment (460 nm, 30 μW/cm²) from 20:00–22:00 h while salivary melatonin and cortisol are sampled every 20 min.
- We predict that wild‑type subjects will show a ≥2‑hour DLMO advance after morning light and a





























